FierceBiotech

Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout

Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease after a registrational trial showed “highly statistically significant” ...
Seeking Alpha

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

EMERYVILLE, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune ...
Nasdaq

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H 2026 ...
Seeking Alpha

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a devastating neuroimmunological autoimmune disease KYV-101 is a fully human ...
FierceBiotech

JPM25: Kyverna's new CEO sets priorities for cell therapy biotech riding the autoimmune wave

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the California biotech, which aims to deliver the first approved CAR-T therapy in an ...